Gradient phenomenon of multidrug resistance gene expression in breast cancer during neoadjuvant chemotherapy is related to disease progression

Gradient phenomenon of multidrug resistance gene expression in breast cancer during neoadjuvant chemotherapy is related to disease progression

Bibliographic Details
Main Author:	N. V. Litviakov
Format:	Article
Language:	Russian
Published:	Russian Academy of Sciences, Tomsk National Research Medical Center 2016-02-01
Series:	Сибирский онкологический журнал
Subjects:	гены множественной лекарственной устойчивости рак молочной железы неоадъювантная химиотерапия безметастатическая выживаемость
Online Access:	https://www.siboncoj.ru/jour/article/view/162

Similar Items

IMMEDIATE RESPONSE TO NEOADJUVANT CHEMOTHERAPY INCLUDING CAPECITABINE AND LONG-TERM TREATMENT OUTCOMES OF OPERABLE BREAST CANCER
by: E. M. Slonimskaya, et al.
Published: (2016-07-01)

EXSPRESSION OF MDR-GENES AND MONORESISTANCE GENES IN NON-SMALL-CELL LUNG CANCER
by: E. L. Yumov, et al.
Published: (2016-02-01)

Whole transcriptome analysis of breast tumors during neoadjuvant chemotherapy: association with response to preoperative chemotherapy
by: M. K. Ibragimova, et al.
Published: (2022-03-01)

Impact of various options of neoadjuvant chemotherapy on the hormonal status of patients with breast cancer
by: Yu. S. Sidorenko, et al.
Published: (2014-08-01)

NEOADJUVANT CHEMOTHERAPY WITH RADICAL CYSTECTOMY IN THE TREATMENT OF MUSCLE-INVASIVE BLADDER CANCER
by: N. S. Nurgaliev, et al.
Published: (2016-10-01)

Long-term results of complete clinical and pathologic regression in patients with breast cancer
by: S. M. Demidov, et al.
Published: (2016-09-01)

Correlation of the value of sonoelastography strain ratio with the degree of pathological regression in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy
by: E. A. Bus’ko, et al.
Published: (2017-02-01)

BRCA1 mRNA expression levels as an predictor of response to neoadjuvant chemotherapy in breast cancer
by: M. M. Tsyganov, et al.
Published: (2018-05-01)

RELATIONSHIP OF THE IMMUNOLOGICAL PARAMETRES WITH NEOADJUVANT CHEMOTHERAPY EFFECTIVENESS IN BREAST CANCER PATIENTS
by: Y. V. Kukharev, et al.
Published: (2016-02-01)

MICROARRAY ANALYSIS OF DNA COPY NUMBER ABERRATION IN BREAST TUMOR: CORRELATION WITH THE EFFICACY OF NEOADJUVANT CHEMOTHERAPY
by: N. V. Litviakov, et al.
Published: (2016-02-01)

Time course of changes in 6-sulfatoxymelatonin excretion in patients with breast cancer after various neoadjuvant chemotherapy options
by: Yu. S. Sidorenko, et al.
Published: (2014-07-01)

Aberrations of the number of copies (CNA) in the genome of luminal B breast tumor
by: M. K. Ibragimova, et al.
Published: (2020-10-01)

Predictive and prognostic significance of loss of heterozygosity in ABC transporter genes in breast cancer
by: M. M. Tsyganov, et al.
Published: (2022-11-01)

Magnetic resonance imaging in evaluation of efficiency of neoadjuvant chemotherapy of breast cancer
by: A. V. Komyahov, et al.
Published: (2015-12-01)

Neoadjuvant treatment for breast cancer
by: V. F. Semiglazov, et al.
Published: (2014-07-01)

Role of positron emission tomography in predicting early tumor response to neoadjuvant chemotherapy for breast cancer
by: N. G. Chanchikova, et al.
Published: (2021-01-01)

PREDICTIVE VALUE OF MOLECULAR PARAMETERS IN PATIENTS WITH BASAL-LIKE TRIPL-NEGATIVE BREAST CANCER
by: О. D. Bragina, et al.
Published: (2016-02-01)

The prognostic significance of BRCA1 gene expression in patients with breast cancer
by: M. M. Tsyganov, et al.
Published: (2019-07-01)

Gene expression analysis of ABC transporter family in breast tumors: relationship with chemotherapy effect and disease prognosis
by: M. M. Tsyganov, et al.
Published: (2020-09-01)

ASSOCIATION OF NKT- AND ACTIVATED CD25<sup>+</sup> PERIPHERAL BLOOD LYMPHOCYTES WITH DISEASE FREE AND OVERALL SURVIVAL OF TRIPLE NEGATIVE BREAST CANCER PATIENTS
by: A. I. Chertkova, et al.
Published: (2020-12-01)

Intensified dose-dense neoadjuvant chemotherapy using paclitaxel-gemcitabine and docetaxel-doxorubicin combinations for locally advanced breast cancer
by: I. V. Frai, et al.
Published: (2014-07-01)

COMPARATIVE ANALYSIS OF DIFFERENT NEOADJUVANT CHEMOTHERAPY REGIMENS FOR TRIPLE-NEGATIVE BREAST CANCER
by: P. V. Krivorotko, et al.
Published: (2017-12-01)

The role of neoadjuvant chemotherapy of triple-negative breast cancer in St. Petersburg City Clinical Oncological Dispensary
by: A. G. Manikhas, et al.
Published: (2016-09-01)

The multidrug resistance proteins Pgp, MRP, and BCRP as markers for lowering the efficacy of tamoxifen in the treatment of breast cancer
by: T. A. Bogush, et al.
Published: (2014-07-01)

mRNA expression of chemosensitivity genes as a predictor of response to neoadjuvant chemotherapy in non-small cell lung cancer
by: M. M. Tsyganov, et al.
Published: (2019-02-01)

Taxanes in adjuvant and neoadjuvant therapy for breast cancer
by: S. V. Limareva
Published: (2014-08-01)

STAGE IB2–IIIB CERVICAL CANCER: NEOADJUVANT CHEMOTHERAPY, RADICAL SURGERY AND PATIENT SURVIVAL
by: D. L. Ovodenko, et al.
Published: (2021-06-01)

Opyt primeneniya Taksotera v kombinatsii s doksorubitsinom v kachestve khimioterapii 1-y linii u bol'nykh metastaticheskim rakom molochnoy zhelezy
by: V M Samoylenko, et al.
Published: (2006-03-01)

INTRA-ATERIAL CHEMOTHERAPY OF THE BREAST CANCER
by: Shamil Kh. Gantsev, et al.
Published: (2017-09-01)

The role of epidermal growth factor receptor (EGFR) in the efficacy of neoadjuvant chemotherapy in triple-negative breast cancer patients
by: N. N. Babyshkina, et al.
Published: (2020-04-01)

News on preoperative chemotherapy for breast cancer: according to the proceedings of the 33rd Annual Breast Cancer Symposium (December 8–12, 2010, San-Antonio, USA)
by: S. M. Portnoy
Published: (2014-07-01)

A PARADIGM SHIFT IN THE TREATMENT OF PATIENTS WITH RESECTABLE PANCREATIC CANCER
by: E. Yu. Antonova, et al.
Published: (2020-07-01)

Preoperative Hormone Therapy in the Treatment of Breast Cancer: What Do We Know So Far?
by: V. V. Vorotnikov, et al.
Published: (2022-10-01)

BREAST-CONSERVING SURGERY AFTER NEOADJUVANT CHEMOTHERAPY IN BREAST CANCER PATIENTS
by: A. R. Bosieva, et al.
Published: (2021-08-01)

Combination chemotherapy in the treatment of breast cancer patients with metastatic brain involvement and a poor prognosis
by: D. R. Naskhletashvili, et al.
Published: (2014-07-01)

Phenomenon of loss of heterozygosity in tumour tissue of breast cancer: association with expression of monoresistance genes
by: M. M. Tsyganov, et al.
Published: (2018-01-01)

STUDY OF CHANGES IN TUMOR BLOOD FLOW FOR THE ASSESSMENT OF EARLY RESPONSE TO NEOADJUVANT CHEMOTHERAPY IN BREAST CANCER PATIENTS
by: M. V. Pavlov, et al.
Published: (2020-12-01)

Efficacy and safety of cisplatin and paclitaxel (PlaTax regimen) in the neoadjuvant treatment of patients with stage II–III triple-negative breast cancer
by: O. O. Gordeeva, et al.
Published: (2020-11-01)

Clinical and morphological characteristics and prognosis of BRCA-associated breast cancer in women of the reproductive age
by: D. E. Avtomonov, et al.
Published: (2014-07-01)

Changes in sonoelastography indices of stiffness as a criterion of evaluation of efficiency of neoadjuvant chemotherapy for breast cancer
by: E. A. Bus'ko, et al.
Published: (2014-03-01)